肺癌内科治疗进展.pptVIP

非小细胞肺癌内科治疗进展;化疗进展;辅助治疗的必要性;辅助化疗;BRCA1水平和含铂药物化疗的相关性;Customized BRCA1 Adjuvant Treatment in Stage II-II NSCLC (SCAT);Presented By Mark Socinski at 2015 ASCO Annual Meeting;实验组的OS;Massuti B, et al. 2015 ASCO Abstract 7507.;Massuti B, et al. 2015 ASCO Abstract 7507.;分子学分析指导下的晚期NSCLC患者全球III期研究：研究设计;研究结果：PFS和OS;So what can we conclude from this study and what are the issues?;化疗进展;Unresectable Stage III NSCLC; ;不可手术的III期NSCLC;Is CisPem “worthy” of a Phase III Trial in stage III NSCLC?;PROCLAIM: Study Design;Presented By Mark Socinski at 2015 ASCO Annual Meeting;PROCLAIM: Primary Endpoint, OS;PROCLAIM in the wake of RTOG 0617;化疗进展;WJOG5208L: Study design;Baseline characteristics;Primary endpoint: Overall survival;Progression-free survival;Objective tumor response;Treatment exposure;Post-Study Systemic Therapy;CA031试验设计;主要终点ORR--所有组织学类型;主要终点ORR--组织学分层;化疗方案的选择;化疗方案的选择;化疗方案的选择;PARAMOUNT研究：力比泰同药维持治疗显著延长非鳞癌(EGFR突变状态未知)患者PFS;PARAMOUNT研究：力比泰同药维持治疗显著延长非鳞癌(EGFR突变状态未知)患者OS;Single-agent Pl;Exploratory EGFR biomarker analysis: PFS;Median OS was 24.3 vs 27.5 months for B+CP vs Pl+CP in the EGFR mutation-positive subgroup (HR 0.90) In the EGFR wild-type subgroup, median OS was 20.3 vs 13.8 months for B+CP vs Pl+CP (HR 0.57) ;Plasma samples were available from 274 patients Plasma VEGF-A and VEGFR-2 baseline levels (high versus low compared to median levels) did not correlate with bevacizumab efficacy for PFS or OS ;化疗进展;Mutational heterogeneity in cancer;适应性免疫应答可以预测预后;克服免疫逃逸的根本 — 解除T细胞的抑制;Target;免疫检查点及其抗体;;PD-L1表达量与OS/PFS的关系;Nivolumab二线治疗非鳞型NSCLC的III期临床研究CheckMate 057;0.25;PD-L1的疗效预测指标并没有在鳞癌体现（017研究）而在非鳞癌体现（057）;结论;谢谢大家